Rezultati pretraživanja
  1. Osobe Vidi sve

  2. prije 18 minuta

    PharmaScrip: Biogen's Tecfidera Safe Following IPR Decision – For Now  

  3. prije 18 minuta

    PharmaScrip: Executives On The Move: Bayer Names Upcoming Information Chief And Legal Hires At Eli Lilly And CytoDyn  

  4. prije 4 minute

    Best Practices In Seasonal Vaccine Efficacy Studies: Tips For Successful Planning And Execution

  5. prije 3 sata

    PharmaScrip: Merck: It’s Not Just Keytruda Driving Future Growth  

  6. prije 3 sata

    PharmaScrip: Merck To Spin Out A New Company, Following Industry's Downsizing Trend  

  7. prije 18 minuta

    PharmaScrip: Zydus Cadila Explores Orphan Drug Indication For NASH Candidate  

  8. prije 15 sati

    PharmaScrip: Novo Nordisk’s Positive Q4 Update Highlights Pipeline Plans  

  9. prije 17 sati

    Pharma Is Priority As GSK Confirms Split With Consumer

  10. prije 18 sati

    PharmaScrip: Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell  

  11. prije 21 sat

    PharmaScrip: Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits  

  12. prije 21 sat

    PharmaScrip: Leo Sets Up For A David & Goliath Showdown In Atopic Dermatitis  

  13. 5. velj

    PharmaScrip: Coronavirus Notebook: Regeneron, HHS To Develop Antibody  

  14. 5. velj

    PharmaScrip: Ranitidine Recall Dents GSK India, Which Mulls Plant Sale  

  15. 5. velj

    PharmaScrip: Japan Pharma Unconcerned About Virus Impact - For Now  

  16. 5. velj

    PharmaScrip: Gilead Writes Down Kite Buy As Yescarta Sales Flatten Out  

  17. 4. velj

    PharmaScrip: Freeline Bags Alnylam's Heggie As CEO  

  18. 4. velj

    PharmaScrip: Sanofi Q4 Preview: CEO Hudson’s Planned Revamp Key Focus  

  19. 4. velj

    PharmaScrip: Insmed Goes Full Steam Ahead With Bronchiectasis Candidate  

  20. 4. velj

    PharmaScrip: United Therapeutics' Unituxin Disappoints In SCLC  

  21. 4. velj

    PharmaScrip: Podcast: Key Takeaways From J.P. Morgan  

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.